ClinicalTrials.gg
RecruitingNCT06954103MAP-SHSUpdated May 1, 2025

Mechanisms And Prognosis of Stroke-Heart Syndrome

An observational study in Stroke, Myocardial Injury and Heart Failure, sponsored by Chensheng Pan. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Chensheng Pan · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
658
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Planned enrollment
88th of 180
658 · median 611
Started
2025
with 71 others
Observational
181 of 613
78 open now
Primary completion
2028-03
later than 207 of 262 live
Registered
488th of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 88th largest by planned enrollment of the 180 observational ones that give a count, is one of 72 that started in 2025, is one of 181 observational ones, reaches primary completion later than 207 of the 262 other live ones, and was the 488th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.

03

Conditions studied

  • Stroke
  • Myocardial Injury
  • Heart Failure
  • Acute Coronary Syndromes
  • Arrhythmia
  • Sudden Cardiac Death
  • Takotsubo Syndrome
  • Heart Rate Variability

Keywords

  • Stroke-heart syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be selected from the neurology outpatient clinic, emergency department, and intensive care unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients admitted within 48 hours of onset, confirmed by CT/MRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke).
  2. Moderate-to-severe stroke with NIHSS ≥ 5.

Exclusion criteria

Exclusion Criteria:

  1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.).
  2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.).
  3. (TIA) and subarachnoid hemorrhage (SAH).
  4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms).
  5. Concomitant systemic diseases such as renal failure ( \< 30), disorders, severe infections, etc.
  6. History of dementia, depression, or other psychiatric disorders.
  7. Poor compliance and inability to cooperate with follow-up.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
658 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. blood high-sensitivity cardiac troponin level

    a marker of acute myocardial injury

    Time frame: within 48 hours and at 72 hours after stroke onset

  2. left ventricular ejection fraction

    measured by transthoracic echocardiography; a marker of ventricular dysfunction and heart failure

    Time frame: within 1 week after stroke onset

  3. blood N-terminal pro-brain natriuretic peptide (NT-proBNP) level

    a marker of ventricular dysfunction and heart failure

    Time frame: within 1 week after stroke onset

  4. functional outcome

    measured by modified Rankin scale (mRS), a 7-level ordinal scale (scores 0-6) used to assess global disability after stroke. Higher scores indicate worse functional outcome.

    Time frame: 3 months and 1 year after stroke onset.

  5. death

    Time frame: 1 month, 3 months and 1 year after stroke onset

Secondary outcomes

  1. post-stroke cognitive impairment

    measured by Montreal Cognitive Assessement (MoCA), a widely used screening tool designed to detect mild cognitive impairment and dementia. MoCA score range: 0-30, higher scores indicate better cognitive function.

    Time frame: 3 months and 1 year after stroke onset.

  2. post-stroke depression

    measured by Hamilton depression rating scale (HAMD), a widely used clinician-administered tool for assessing the severity of depression. HAMD score range: 0-52. Higher scores indicate higher depression severity.

    Time frame: 3 months and 1 year after stroke onset.

  3. post-stroke anxiety

    measured by Hamilton anxiety rating scale (HAMA), a clinician-administered tool to assess the severity of anxiety symptoms. HAMA score range: 0-56. Higher scores indicate higher anxiety severity.

    Time frame: 3 months and 1 year after stroke onset.

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 36 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
May 1, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Apr 1, 2028
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06954103
Lead sponsor
Chensheng Pan
Collaborators
National Natural Science Foundation of China
Responsible party
Chensheng Pan (Professor, Tongji Hospital) — Sponsor-investigator
First posted
May 1, 2025
Start date
Mar 1, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
May 1, 2025

Study contacts

Chensheng Pan, M.D.
Contact
pancs29@gmail.com
+8618202738845
Zhou Zhu, MD, PhD
Contact
zhouzhu@hust.edu.cn
+86 18171081029
Zhou Zhu, MD, PhD
principal investigator · Tongji Hospital, Tongji Medical College, Huazhong University of Science and Tech

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion